AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Venu Holding Corporation (NYSE American: VENU) filed a Form 8-K dated 18 June 2025 to furnish an updated corporate overview presentation (Exhibit 99.1). The presentation will be used in meetings with prospective investors and strategic partners and highlights the Company’s ongoing Regulation A offering of its Series A 8.0% Cumulative Redeemable Convertible Preferred Stock.

  • The preferred shares carry an 8.0% cumulative dividend and are convertible; detailed terms are contained in the Form 1-A offering circular.
  • The Company intends to apply to list the Series A Preferred on NYSE American under the ticker â€�VENU.PR Aâ€� after the final closing, but listing approval and market liquidity are not guaranteed.
  • Management stresses that the securities are highly speculative; investors could lose their entire investment and may face prolonged illiquidity.
  • The furnished material is provided under Item 7.01 (Reg FD); it is not deemed “filedâ€� for liability purposes and is exempt from Section 18 of the Exchange Act.
  • Extensive forward-looking-statement disclaimers reference project execution, financial performance and regulatory risks; readers are directed to the Form 1-A risk factors.

No financial results, revenue figures or operational updates were included in this report.

Venu Holding Corporation (NYSE American: VENU) ha presentato un modulo 8-K datato 18 giugno 2025 per fornire un aggiornamento della presentazione aziendale (Allegato 99.1). La presentazione sarà utilizzata negli incontri con potenziali investitori e partner strategici e mette in evidenza l’attuale offerta Regulation A della Serie A 8,0% Azioni Preferenziali Convertibili Cumulative Riscattabili della Società.

  • Le azioni privilegiate prevedono un dividendo cumulativo dellâ€�8,0% e sono convertibili; i termini dettagliati sono contenuti nel prospetto di offerta Form 1-A.
  • La Società intende richiedere la quotazione della Serie A Preferred su NYSE American con il simbolo â€�VENU.PR Aâ€� dopo la chiusura finale, ma l’approvazione della quotazione e la liquidità di mercato non sono garantite.
  • La direzione sottolinea che i titoli sono altamente speculativi; gli investitori potrebbero perdere l’intero investimento e affrontare una prolungata illiquidità.
  • Il materiale fornito è presentato ai sensi dell’Elemento 7.01 (Reg FD); non è considerato “depositatoâ€� ai fini di responsabilità ed è esente dalla Sezione 18 del Exchange Act.
  • Vengono fornite ampie esclusioni di responsabilità sulle dichiarazioni previsionali riguardanti l’esecuzione dei progetti, le performance finanziarie e i rischi normativi; si rimanda ai fattori di rischio del Form 1-A.

Nel rapporto non sono stati inclusi risultati finanziari, dati sui ricavi o aggiornamenti operativi.

Venu Holding Corporation (NYSE American: VENU) presentó un Formulario 8-K fechado el 18 de junio de 2025 para proporcionar una presentación corporativa actualizada (Exhibición 99.1). La presentación se utilizará en reuniones con posibles inversores y socios estratégicos y destaca la oferta Regulation A en curso de la Serie A de acciones preferentes convertibles rescatables acumulativas al 8.0% de la Compañía.

  • Las acciones preferentes pagan un dividendo acumulativo del 8.0% y son convertibles; los términos detallados se encuentran en el prospecto de oferta Form 1-A.
  • La Compañía planea solicitar la cotización de la Serie A Preferred en NYSE American bajo el símbolo â€�VENU.PR Aâ€� tras el cierre final, aunque la aprobación de la cotización y la liquidez del mercado no están garantizadas.
  • La dirección enfatiza que los valores son altamente especulativos; los inversores podrían perder toda su inversión y enfrentar una prolongada iliquidez.
  • El material proporcionado se presenta bajo el Ãtem 7.01 (Reg FD); no se considera ‼õ°ù±ð²õ±ð²Ô³Ù²¹»å´Çâ€� a efectos de responsabilidad y está exento de la Sección 18 de la Ley de Intercambio.
  • Se incluyen amplias exenciones sobre declaraciones prospectivas relacionadas con la ejecución del proyecto, desempeño financiero y riesgos regulatorios; se remite a los factores de riesgo del Form 1-A.

No se incluyeron resultados financieros, cifras de ingresos ni actualizaciones operativas en este informe.

Venu Holding Corporation (NYSE American: VENU)ëŠ� 2025ë…� 6ì›� 18ì¼ìž Form 8-Kë¥� 제출하여 최신 기업 개요 프레젠테ì´ì…˜ (ì¦ë¹™ìžë£Œ 99.1)ì� 제공했습니다. ì� 프레젠테ì´ì…˜ì€ 잠재 투ìžìž� ë°� ì „ëžµì � 파트너와ì� 미팅ì—서 사용ë˜ë©°, 회사ì� ì§„í–‰ ì¤‘ì¸ Regulation A 공모ì� Series A 8.0% ëˆ„ì  ìƒí™˜ ê°€ëŠ� 전환 ìš°ì„ ì£�ë¥� 강조합니ë‹�.

  • 우선주는 8.0% ëˆ„ì  ë°°ë‹¹ê¸ˆì„ ì§€ê¸‰í•˜ë©� 전환 가능하ë©�, ìžì„¸í•� ì¡°ê±´ì€ Form 1-A 공모 ì„¤ëª…ì„œì— í¬í•¨ë˜ì–´ 있습니다.
  • 회사ëŠ� 최종 ë§ˆê° í›� Series A Preferred 주ì‹ì� NYSE Americanì—� â€�VENU.PR Aâ€� 티커ë¡� ìƒìž¥ ì‹ ì²­í•� 계íšì´ë‚˜, ìƒìž¥ ìŠ¹ì¸ ë°� 시장 유ë™ì„±ì€ 보장ë˜ì§€ 않습니다.
  • ê²½ì˜ì§„ì€ í•´ë‹¹ ì¦ê¶Œì� 매우 투기ì �ìž„ì„ ê°•ì¡°í•˜ë©°, 투ìžìžëŠ” ì „ì•¡ ì†ì‹¤ 가능성ê³� 장기ê°� 유ë™ì„� ë¶€ì¡±ì— ì§ë©´í•� ìˆ� 있습니다.
  • 제공ë� ìžë£ŒëŠ� 항목 7.01(Reg FD)ì—� ë”°ë¼ ì œê³µë˜ì—ˆìœ¼ë©°, ë²•ì  ì±…ìž„ 목ì ìƒ� ‵Ӡœì¶œëœâ€� 것으ë¡� 간주ë˜ì§€ 않고 ì¦ê¶Œê±°ëž˜ë²� 섹션 18ì� ë©´ì œë¥� 받습니다.
  • 프로ì íЏ 실행, 재무 성과 ë°� 규제 위험ê³� ê´€ë ¨ëœ ê´‘ë²”ìœ„í•œ 미래 예측 진술 ë©´ì±… ì¡°í•­ì� í¬í•¨ë˜ì–´ 있으ë©�, ìžì„¸í•� 위험 요소ëŠ� Form 1-Aë¥� 참조하시ê¸� ë°”ëžë‹ˆë‹¤.

ë³� 보고서ì—ëŠ� 재무 실ì , ìˆ˜ìµ ìˆ˜ì¹˜ ë˜ëŠ” ìš´ì˜ ì—…ë°ì´íŠ¸ê°€ í¬í•¨ë˜ì§€ 않았습니ë‹�.

Venu Holding Corporation (NYSE American : VENU) a déposé un formulaire 8-K daté du 18 juin 2025 afin de fournir une présentation d’entreprise mise à jour (Annexe 99.1). Cette présentation sera utilisée lors de réunions avec des investisseurs potentiels et des partenaires stratégiques, et met en avant l’offre en cours de Réglementation A portant sur ses actions privilégiées convertibles rachetables cumulatives Série A à 8,0 %.

  • Les actions privilégiées offrent un dividende cumulatif de 8,0 % et sont convertibles ; les modalités détaillées figurent dans le prospectus d’offre Formulaire 1-A.
  • La Société envisage de demander la cotation des actions Série A Preferred sur NYSE American sous le symbole « VENU.PR A » après la clôture finale, mais l’approbation de la cotation et la liquidité du marché ne sont pas garanties.
  • La direction souligne que ces titres sont hautement spéculatifs ; les investisseurs pourraient perdre la totalité de leur investissement et faire face à une illiquidité prolongée.
  • Le matériel fourni est présenté en vertu de l’élément 7.01 (Reg FD) ; il n’est pas considéré comme « déposé » aux fins de responsabilité et est exempté de la section 18 du Exchange Act.
  • De nombreuses clauses de non-responsabilité relatives aux déclarations prospectives font référence à l’exécution du projet, aux performances financières et aux risques réglementaires ; les lecteurs sont invités à consulter les facteurs de risque du Formulaire 1-A.

Aucun résultat financier, chiffre d’affaires ou mise à jour opérationnelle n’a été inclus dans ce rapport.

Venu Holding Corporation (NYSE American: VENU) reichte am 18. Juni 2025 ein Formular 8-K ein, um eine aktualisierte ±«²Ô³Ù±ð°ù²Ô±ð³ó³¾±ð²Ô²õü²ú±ð°ù²õ¾±³¦³ó³Ù²õ±è°ùä²õ±ð²Ô³Ù²¹³Ù¾±´Ç²Ô (Anlage 99.1) bereitzustellen. Die Präsentation wird in Meetings mit potenziellen Investoren und strategischen Partnern verwendet und hebt das laufende Regulation A-Angebot der Serie A 8,0% kumulative rückzahlbare wandelbare Vorzugsaktien des Unternehmens hervor.

  • Die Vorzugsaktien bieten eine kumulative Dividende von 8,0 % und sind wandelbar; detaillierte Bedingungen sind im Form 1-A Angebotsprospekt enthalten.
  • Das Unternehmen beabsichtigt, die Serie A Preferred nach dem endgültigen Abschluss unter dem Ticker â€�VENU.PR Aâ€� an der NYSE American zu listen, jedoch sind die Listungszusage und die Marktliquidität nicht garantiert.
  • Das Management betont, dass die Wertpapiere hoch spekulativ sind; Investoren könnten ihre gesamte Investition verlieren und eine längere Illiquidität erleben.
  • Das bereitgestellte Material wird unter Punkt 7.01 (Reg FD) bereitgestellt; es gilt nicht als „e¾±²Ô²µ±ð°ù±ð¾±³¦³ó³Ùâ€� im Haftungsrecht und ist von Abschnitt 18 des Exchange Act ausgenommen.
  • Umfangreiche Haftungsausschlüsse für zukunftsgerichtete Aussagen beziehen sich auf Projektdurchführung, finanzielle Leistung und regulatorische Risiken; Leser werden auf die Risikofaktoren im Form 1-A verwiesen.

In diesem Bericht wurden keine Finanzergebnisse, Umsatzzahlen oder operative Updates enthalten.

Positive
  • Launch of Series A 8.0% cumulative redeemable convertible preferred stock offering provides a potential new capital source.
  • Intent to list the preferred shares on NYSE American could enhance visibility and liquidity if approved.
  • Updated investor presentation may improve market communication and attract strategic partners.
Negative
  • Listing is not assured; the preferred shares may remain illiquid.
  • The filing emphasises high investment risk and possibility of total loss.
  • No new financial metrics or performance updates, limiting investor insight.

Insights

TL;DR: Neutral disclosure; capital-raise pathway outlined, but no concrete financial data.

The 8-K merely furnishes an investor deck tied to a Reg A preferred stock raise. While an 8% cumulative dividend and a potential NYSE American listing could appeal to yield-seeking investors, the filing offers no fresh operating metrics or guidance. The disclaimer-heavy language underscores execution and liquidity risks, and listing approval remains uncertain. Given the absence of financial performance data, the event is informational rather than market-moving.

TL;DR: Standard Reg FD compliance; limited governance impact.

Management follows best practice by isolating forward-looking statements and clarifying that the deck is "furnished"—not "filed"—thus limiting liability. The explicit risk language and reference to SEC-qualified Form 1-A suggests an effort to maintain transparency with retail investors under Regulation A. However, the speculative nature of the preferred shares and uncertain exchange listing could attract regulatory scrutiny if expectations are mis-set. Overall, routine governance execution with no immediate red flags.

Venu Holding Corporation (NYSE American: VENU) ha presentato un modulo 8-K datato 18 giugno 2025 per fornire un aggiornamento della presentazione aziendale (Allegato 99.1). La presentazione sarà utilizzata negli incontri con potenziali investitori e partner strategici e mette in evidenza l’attuale offerta Regulation A della Serie A 8,0% Azioni Preferenziali Convertibili Cumulative Riscattabili della Società.

  • Le azioni privilegiate prevedono un dividendo cumulativo dellâ€�8,0% e sono convertibili; i termini dettagliati sono contenuti nel prospetto di offerta Form 1-A.
  • La Società intende richiedere la quotazione della Serie A Preferred su NYSE American con il simbolo â€�VENU.PR Aâ€� dopo la chiusura finale, ma l’approvazione della quotazione e la liquidità di mercato non sono garantite.
  • La direzione sottolinea che i titoli sono altamente speculativi; gli investitori potrebbero perdere l’intero investimento e affrontare una prolungata illiquidità.
  • Il materiale fornito è presentato ai sensi dell’Elemento 7.01 (Reg FD); non è considerato “depositatoâ€� ai fini di responsabilità ed è esente dalla Sezione 18 del Exchange Act.
  • Vengono fornite ampie esclusioni di responsabilità sulle dichiarazioni previsionali riguardanti l’esecuzione dei progetti, le performance finanziarie e i rischi normativi; si rimanda ai fattori di rischio del Form 1-A.

Nel rapporto non sono stati inclusi risultati finanziari, dati sui ricavi o aggiornamenti operativi.

Venu Holding Corporation (NYSE American: VENU) presentó un Formulario 8-K fechado el 18 de junio de 2025 para proporcionar una presentación corporativa actualizada (Exhibición 99.1). La presentación se utilizará en reuniones con posibles inversores y socios estratégicos y destaca la oferta Regulation A en curso de la Serie A de acciones preferentes convertibles rescatables acumulativas al 8.0% de la Compañía.

  • Las acciones preferentes pagan un dividendo acumulativo del 8.0% y son convertibles; los términos detallados se encuentran en el prospecto de oferta Form 1-A.
  • La Compañía planea solicitar la cotización de la Serie A Preferred en NYSE American bajo el símbolo â€�VENU.PR Aâ€� tras el cierre final, aunque la aprobación de la cotización y la liquidez del mercado no están garantizadas.
  • La dirección enfatiza que los valores son altamente especulativos; los inversores podrían perder toda su inversión y enfrentar una prolongada iliquidez.
  • El material proporcionado se presenta bajo el Ãtem 7.01 (Reg FD); no se considera ‼õ°ù±ð²õ±ð²Ô³Ù²¹»å´Çâ€� a efectos de responsabilidad y está exento de la Sección 18 de la Ley de Intercambio.
  • Se incluyen amplias exenciones sobre declaraciones prospectivas relacionadas con la ejecución del proyecto, desempeño financiero y riesgos regulatorios; se remite a los factores de riesgo del Form 1-A.

No se incluyeron resultados financieros, cifras de ingresos ni actualizaciones operativas en este informe.

Venu Holding Corporation (NYSE American: VENU)ëŠ� 2025ë…� 6ì›� 18ì¼ìž Form 8-Kë¥� 제출하여 최신 기업 개요 프레젠테ì´ì…˜ (ì¦ë¹™ìžë£Œ 99.1)ì� 제공했습니다. ì� 프레젠테ì´ì…˜ì€ 잠재 투ìžìž� ë°� ì „ëžµì � 파트너와ì� 미팅ì—서 사용ë˜ë©°, 회사ì� ì§„í–‰ ì¤‘ì¸ Regulation A 공모ì� Series A 8.0% ëˆ„ì  ìƒí™˜ ê°€ëŠ� 전환 ìš°ì„ ì£�ë¥� 강조합니ë‹�.

  • 우선주는 8.0% ëˆ„ì  ë°°ë‹¹ê¸ˆì„ ì§€ê¸‰í•˜ë©� 전환 가능하ë©�, ìžì„¸í•� ì¡°ê±´ì€ Form 1-A 공모 ì„¤ëª…ì„œì— í¬í•¨ë˜ì–´ 있습니다.
  • 회사ëŠ� 최종 ë§ˆê° í›� Series A Preferred 주ì‹ì� NYSE Americanì—� â€�VENU.PR Aâ€� 티커ë¡� ìƒìž¥ ì‹ ì²­í•� 계íšì´ë‚˜, ìƒìž¥ ìŠ¹ì¸ ë°� 시장 유ë™ì„±ì€ 보장ë˜ì§€ 않습니다.
  • ê²½ì˜ì§„ì€ í•´ë‹¹ ì¦ê¶Œì� 매우 투기ì �ìž„ì„ ê°•ì¡°í•˜ë©°, 투ìžìžëŠ” ì „ì•¡ ì†ì‹¤ 가능성ê³� 장기ê°� 유ë™ì„� ë¶€ì¡±ì— ì§ë©´í•� ìˆ� 있습니다.
  • 제공ë� ìžë£ŒëŠ� 항목 7.01(Reg FD)ì—� ë”°ë¼ ì œê³µë˜ì—ˆìœ¼ë©°, ë²•ì  ì±…ìž„ 목ì ìƒ� ‵Ӡœì¶œëœâ€� 것으ë¡� 간주ë˜ì§€ 않고 ì¦ê¶Œê±°ëž˜ë²� 섹션 18ì� ë©´ì œë¥� 받습니다.
  • 프로ì íЏ 실행, 재무 성과 ë°� 규제 위험ê³� ê´€ë ¨ëœ ê´‘ë²”ìœ„í•œ 미래 예측 진술 ë©´ì±… ì¡°í•­ì� í¬í•¨ë˜ì–´ 있으ë©�, ìžì„¸í•� 위험 요소ëŠ� Form 1-Aë¥� 참조하시ê¸� ë°”ëžë‹ˆë‹¤.

ë³� 보고서ì—ëŠ� 재무 실ì , ìˆ˜ìµ ìˆ˜ì¹˜ ë˜ëŠ” ìš´ì˜ ì—…ë°ì´íŠ¸ê°€ í¬í•¨ë˜ì§€ 않았습니ë‹�.

Venu Holding Corporation (NYSE American : VENU) a déposé un formulaire 8-K daté du 18 juin 2025 afin de fournir une présentation d’entreprise mise à jour (Annexe 99.1). Cette présentation sera utilisée lors de réunions avec des investisseurs potentiels et des partenaires stratégiques, et met en avant l’offre en cours de Réglementation A portant sur ses actions privilégiées convertibles rachetables cumulatives Série A à 8,0 %.

  • Les actions privilégiées offrent un dividende cumulatif de 8,0 % et sont convertibles ; les modalités détaillées figurent dans le prospectus d’offre Formulaire 1-A.
  • La Société envisage de demander la cotation des actions Série A Preferred sur NYSE American sous le symbole « VENU.PR A » après la clôture finale, mais l’approbation de la cotation et la liquidité du marché ne sont pas garanties.
  • La direction souligne que ces titres sont hautement spéculatifs ; les investisseurs pourraient perdre la totalité de leur investissement et faire face à une illiquidité prolongée.
  • Le matériel fourni est présenté en vertu de l’élément 7.01 (Reg FD) ; il n’est pas considéré comme « déposé » aux fins de responsabilité et est exempté de la section 18 du Exchange Act.
  • De nombreuses clauses de non-responsabilité relatives aux déclarations prospectives font référence à l’exécution du projet, aux performances financières et aux risques réglementaires ; les lecteurs sont invités à consulter les facteurs de risque du Formulaire 1-A.

Aucun résultat financier, chiffre d’affaires ou mise à jour opérationnelle n’a été inclus dans ce rapport.

Venu Holding Corporation (NYSE American: VENU) reichte am 18. Juni 2025 ein Formular 8-K ein, um eine aktualisierte ±«²Ô³Ù±ð°ù²Ô±ð³ó³¾±ð²Ô²õü²ú±ð°ù²õ¾±³¦³ó³Ù²õ±è°ùä²õ±ð²Ô³Ù²¹³Ù¾±´Ç²Ô (Anlage 99.1) bereitzustellen. Die Präsentation wird in Meetings mit potenziellen Investoren und strategischen Partnern verwendet und hebt das laufende Regulation A-Angebot der Serie A 8,0% kumulative rückzahlbare wandelbare Vorzugsaktien des Unternehmens hervor.

  • Die Vorzugsaktien bieten eine kumulative Dividende von 8,0 % und sind wandelbar; detaillierte Bedingungen sind im Form 1-A Angebotsprospekt enthalten.
  • Das Unternehmen beabsichtigt, die Serie A Preferred nach dem endgültigen Abschluss unter dem Ticker â€�VENU.PR Aâ€� an der NYSE American zu listen, jedoch sind die Listungszusage und die Marktliquidität nicht garantiert.
  • Das Management betont, dass die Wertpapiere hoch spekulativ sind; Investoren könnten ihre gesamte Investition verlieren und eine längere Illiquidität erleben.
  • Das bereitgestellte Material wird unter Punkt 7.01 (Reg FD) bereitgestellt; es gilt nicht als „e¾±²Ô²µ±ð°ù±ð¾±³¦³ó³Ùâ€� im Haftungsrecht und ist von Abschnitt 18 des Exchange Act ausgenommen.
  • Umfangreiche Haftungsausschlüsse für zukunftsgerichtete Aussagen beziehen sich auf Projektdurchführung, finanzielle Leistung und regulatorische Risiken; Leser werden auf die Risikofaktoren im Form 1-A verwiesen.

In diesem Bericht wurden keine Finanzergebnisse, Umsatzzahlen oder operative Updates enthalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WITTE OWEN N.

(Last) (First) (Middle)
210 EAST GRAND AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 06/18/2025 A 95,400 (1) (1) Common Stock 95,400 $0 95,400 D
Explanation of Responses:
1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.
Remarks:
Exhibits: Power of Attorney
/s/Earl Douglas, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Venu Holding (VENU) disclose in its June 18, 2025 8-K?

The company furnished an updated corporate overview presentation related to its Regulation A offering of Series A 8.0% cumulative redeemable convertible preferred stock.

What are the key terms of VENU's Series A Preferred Stock?

The shares carry an 8.0% cumulative dividend, are convertible and redeemable; full terms are in the SEC-filed Form 1-A offering circular.

Will VENU's Series A Preferred be listed on an exchange?

Venu intends to apply for NYSE American listing under ticker VENU.PR A, but approval and active trading are not guaranteed.

Is the information in the investor presentation considered "filed" with the SEC?

No. Under Item 7.01 of the 8-K, the presentation is furnished, not filed, and is therefore not subject to Exchange Act Section 18 liability.

What risks did Venu highlight regarding the offering?

Management notes the securities are highly speculative; investors could lose their entire investment, and the shares may be illiquid for an indefinite period.

Where can investors find more details about the offering?

The complete Form 1-A offering circular is available on the SEC’s EDGAR system by searching for "VENU" under Company Filings.
Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Latest SEC Filings

ALLO Stock Data

282.16M
148.74M
17.73%
77.84%
18.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO